Balance Sheet
Cash Flow Statement
Cash from Discontinued OperationsCash from Discontinued OperationsCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Net Income (2018 - 2025)

Addex Therapeutics' Net Income history spans 8 years, with the latest figure at -$4260.2 for Q4 2025.

  • On a quarterly basis, Net Income rose 76.54% to -$4260.2 in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.5 million, a 111.42% decrease, with the full-year FY2025 number at $137911.1, down 98.99% from a year prior.
  • Net Income came in at -$4260.2 for Q4 2025, down from $142225.5 in the prior quarter.
  • The five-year high for Net Income was $15.9 million in Q2 2024, with the low at -$9.1 million in Q4 2023.
  • Historically, Net Income has averaged -$1.7 million across 5 years, with a median of -$2.4 million in 2023.
  • Biggest five-year swings in Net Income: tumbled 237.81% in 2023 and later surged 761.78% in 2024.
  • Year by year, Net Income stood at -$4.8 million in 2021, then soared by 237.36% to $6.6 million in 2022, then plummeted by 237.81% to -$9.1 million in 2023, then surged by 99.8% to -$18155.9 in 2024, then skyrocketed by 76.54% to -$4260.2 in 2025.
  • Business Quant data shows Net Income for ADXN at -$4260.2 in Q4 2025, $142225.5 in Q2 2025, and -$1.6 million in Q1 2025.